← Back to headlines
Bristol-Myers Squibb Sees Mixed Analyst Sentiment, Cramer Notes Buying Opportunities
Pharmaceutical giant Bristol-Myers Squibb (BMY) is experiencing mixed analyst sentiment, with Jim Cramer specifically highlighting recent stock pullbacks as excellent buying opportunities despite broader industry momentum.
28 Mar, 20:51 — 28 Mar, 20:51
Sources
Showing 1 of 1 sources
